ALNY FY 2010 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

FY 2010 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$100M-0.5% YoY

Gross Profit

$100M100.0% margin

Operating Income

-$44M-44.1% margin

Net Income

-$44M-43.5% margin

EPS (Diluted)

$-1.04

Cash Flow

Operating Cash Flow

-$84M

Free Cash Flow

-$89M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$393M

Total Liabilities

$235M

Stockholders' Equity

$158M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$100M	$101M	-0.5%
Gross Profit	$100M	$101M	-0.5%
Operating Income	-$44M	-$48M	+8.4%
Net Income	-$44M	-$48M	+8.6%